The Lancet· @TheLancet · X·· 23 天前AI 评分50
AI 导读
《柳叶刀》转述的一项研究认为,口服丙酮酸激酶激活剂Mitapivat有望成为镰状细胞病有效且便捷的疾病修饰治疗。原文未披露具体疗效数据,仅给出研究链接供查阅。
正文
Mitapivat, an oral pyruvate kinase activator, has the potential to be an effective and convenient disease-modifying treatment for people with sickle cell disease, finds study.
Explore the research: https://spkl.io/60107kyvi
来源:The Lancet · x.com